reports
EQS-News: Marinomed Biotech AG announces results for the 2023 financia...
EQS-News: Marinomed Biotech AG / Key word(s): Annual Results Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets 16.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record years (2022: EUR 11.3 million) Important progress for Carragelose with new di...
EQS-News: Marinomed Biotech AG gibt Ergebnisse für das Geschäftsjahr 2...
EQS-News: Marinomed Biotech AG / Schlagwort(e): Jahresergebnis Marinomed Biotech AG gibt Ergebnisse für das Geschäftsjahr 2023 bekannt und meldet Fortschritte bei Marinosolv und Carragelose Assets 16.04.2024 / 07:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Marinomed Biotech AG gibt Ergebnisse für das Geschäftsjahr 2023 bekannt und meldet Fortschritte bei Marinosolv und Carragelose Assets Umsatz im Geschäftsjahr 2023 bei EUR 9,2 Mio. nach pandemiebedingten Rekordjahren (2022: EUR 11,3 Mio.) Wichtige Fortschritte bei Carragelos...
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
Shandong Dongyue Organosilicon Materials Co Ltd: 1 director
A director at Shandong Dongyue Organosilicon Materials Co Ltd maiden bought 34,000 shares at 7.480CNY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Egyptian For Tourism Resorts: 1 director
A director at Egyptian For Tourism Resorts sold/bought 2,000,000 shares at 0.000EGP and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Sidetarde: 20% increase in revenue for Q1 2024, with SaaS subscription...
Sidetarde: 20% increase in revenue for Q1 2024, with SaaS subscriptions up 20% Robust growth in bookings €3.98 million in New Annual Contract Value (ACV): up 117%With €1.85 million in SaaS bookings (ARR): up 108%And €2.13 million in Services bookings: up 127%Surge in the United States, now representing 60% of total bookings Strong revenue growth, up 20%, with SaaS subscriptions up 20% Buoyant revenue growth in the United States: up 40% Double-digit growth in sales confirmed for 2024 , the global leader in AI-powered Order-to-Cash applications, today announces that it...
Sidetrade : Très forte croissance des prises de commandes (+117% d'ACV...
Sidetrade : Très forte croissance des prises de commandes (+117% d'ACV), du CA (+20%) et des abonnements SaaS (+20%) Très forte croissance des prises de commandes Valeur annuelle de nouveaux contrats signés (ACV) à 3,98 M€ : +117%Dont nouveaux abonnements SaaS (ARR) à 1,85 M€ : +108% Dont prestations de service à 2,13 M€ : +127%Envolée des Etats-Unis avec 60% du total des prises de commandes Forte croissance du CA à +20% +20% pour les abonnements SaaS Très forte croissance des revenus aux Etats-Unis : +40% Croissance à deux chiffres des ventes confirmée pour 2024 ,...
Amundi and Victory Capital announce plan to establish a strategic part...
Amundi and Victory Capital announce plan to establish a strategic partnership Amundi and Victory Capital announce plan to establish a strategic partnership: Amundi US to combine into Victory CapitalAmundi to become a strategic shareholder of Victory CapitalReciprocal 15-year exclusive distribution agreements Paris (France) & San Antonio (Texas, United-States) 16 April 2024, Amundi and Victory Capital (Nasdaq: VCTR) are announcing today that they have signed a Memorandum of Understanding to combine Amundi US into Victory Capital, for Amundi to become a strategic shareholder of Victory Capi...
Amundi et Victory Capital annoncent leur intention de nouer un partena...
Amundi et Victory Capital annoncent leur intention de nouer un partenariat stratégique Amundi et Victory Capital annoncent leur intention de nouer un partenariat stratégique Ce partenariat comprendrait trois volets : La fusion d’Amundi US avec Victory Capital ;Une prise de participation stratégique d’Amundi dans Victory CapitalDes accords de distribution internationaux et réciproques d'une durée de 15 ans entre Amundi et Victory Capital ; Paris (France) & San Antonio (Texas, Etats-Unis) 16 avril 2024, Amundi et Victory Capital annoncent avoir signé un protocole d'accord visant à fusionne...
Inside information, negative profit warning: Oma Savings Bank Plc publ...
Inside information, negative profit warning: Oma Savings Bank Plc publishes preliminary information on the result for the first quarter OMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE, 16 APRIL 2024 AT 8:45 A.M EET, INSIDE INFORMATION Inside information, negative profit warning: Oma Savings Bank Plc publishes preliminary information on the result for the first quarter Oma Savings Bank Plc (OmaSp or the Company) publishes preliminary information on the preliminary result for the first quarter of 2024 due to an additional allowance based on management's judgement to be recognised for the per...
Sisäpiiritieto, negatiivinen tulosvaroitus: Oma Säästöpankki Oyj julka...
Sisäpiiritieto, negatiivinen tulosvaroitus: Oma Säästöpankki Oyj julkaisee ennakkotiedon ensimmäisen neljänneksen tuloksesta OMA SÄÄSTÖPANKKI OYJ, PÖRSSITIEDOTE 16.4.2024 klo 8:45, SISÄPIIRITIETO Sisäpiiritieto, negatiivinen tulosvaroitus: Oma Säästöpankki Oyj julkaisee ennakkotiedon ensimmäisen neljänneksen tuloksesta Oma Säästöpankki Oyj (OmaSp tai Yhtiö) julkaisee ennakkotiedon vuoden 2024 ensimmäisen neljänneksen alustavasta tuloksesta kaudelle kirjattavasta johdon harkintaan perustuvasta lisävarauksesta johtuen. Yhtiö päivittää tulosohjeistustaan, ja vertailukelpoisen tuloksen enn...
Nauticus Robotics Inc: 1 director
A director at Nauticus Robotics Inc maiden bought 100,000 shares at 0.227USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Rowad Tourism (Al Rowad): 1 director
A director at Rowad Tourism (Al Rowad) bought/sold 831,931 shares at 0.000EGP and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
- Luis de Toledo Heras
Enagas : Q1 2024 earnings preview: operating calm, strategic dynamism
>Regulatory framework weighing on results - Enagas will release Q1 2024 results on April 23rd. Our estimates consider the continued decline in regulatory revenues given the 2021-2026 framework (continuity of supply), partially offset by the increase in other regulated revenues, strong activity at the regasification plants, El Musel plant start-up and COPEX adjustments. We expect flattish adjusted EBITDA level considering more stability in recurring costs (after last y...
- Klaus Breitenbach
Berentzen–Gruppe Aktiengesellschaft : First intermediate steps towards...
>Top line and earnings growth in 2024 - Considering the positive development of individual segments, Berentzen projects higher revenue (range: € 190.0m to € 200.0m) for the 2024. It assumes that the spirits segment will experience modest growth, the non-alcoholic beverages and other segments considerable growth, and the fresh juice systems segment substantial growth. The group also expects a positive development for EBITDA (range: € 17.2m to € 19.2m) and EBIT (range: ...
EQS-News: PharmaSGP exceeds the € 100 million revenues mark in 2023 an...
EQS-News: PharmaSGP Holding SE / Key word(s): Preliminary Results/Forecast PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 16.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 Gräfelfing, April 16, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the successful development of previous years in the 2023 financial year and exceeded the € 100 million re...
EQS-News: Nordex Group startet mit Auftragseingang von 2,1 GW in das e...
EQS-News: Nordex SE / Schlagwort(e): Auftragseingänge Nordex Group startet mit Auftragseingang von 2,1 GW in das erste Quartal 2024 16.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, 16. April 2024. Die Nordex Group verzeichnete im ersten Quartal 2024 Auftragseingänge über 338 Windturbinen mit einer Gesamtleistung von 2.086 MW (Q1/2023: 1.021 MW). Der durchschnittliche Verkaufspreis in Euro je Megawatt Leistung (ASP) betrug EUR 0,85 Mio./MW (Q1/2023: EUR 0,90 Mio./MW). Die Nordex Group erhielt Bestellungen a...
EQS-News: PharmaSGP übertrifft 2023 die Umsatzmarke von 100 Mio. EUR u...
EQS-News: PharmaSGP Holding SE / Schlagwort(e): Vorläufiges Ergebnis/Prognose PharmaSGP übertrifft 2023 die Umsatzmarke von 100 Mio. EUR und plant 2024 mit weiterem profitablem Wachstum 16.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PharmaSGP übertrifft 2023 die Umsatzmarke von 100 Mio. EUR und plant 2024 mit weiterem profitablem Wachstum Gräfelfing, 16. April 2024 – Das deutsche OTC-Pharmaunternehmen PharmaSGP Holding SE konnte im Geschäftsjahr 2023 die erfolgreiche Entwicklung der Vorjahre fortsetzen und auf Bas...
EQS-News: Nordex Group starts with order intake of 2.1 GW in the first...
EQS-News: Nordex SE / Key word(s): Incoming Orders Nordex Group starts with order intake of 2.1 GW in the first quarter of 2024 16.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, 16 April 2024. The Nordex Group recorded an order intake of 338 turbines with a total capacity of 2,086 MW in the first quarter of 2024 (Q1/2023: 1,021 MW). The average sales price in euros per megawatt of capacity (ASP) amounted to EUR 0.85 million/MW (Q1/2023: EUR 0.90 million/MW). The Nordex Group received orders from eleven countries....
Braze Inc: 1 director
A director at Braze Inc sold after exercising options/sold 28,383 shares at 42.281USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.